Long-term follow-up of a cohort of HIV-infected patients who discontinued maintenance therapy for cytomegalovirus retinitis

HIV Clinical Trials

Volumn 7, Issue 1, 2006, Pages 1-9

  Walmsley, Sharon L ^a,f,g   Rabound, Janet ^a,b,f   Angel, Jonathan B ^c   Mazzulli, Tony ^a,b,f   Shen, Sandy ^a   Casciaro, Lidia ^a   Young, Charlene D ^c   Moussa, George ^b   Gough, Kevin ^e,f   Rachlis, Anita ^d,f   Hopkins, Jill ^a,d,f  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g NONE   (Canada)

Author keywords

AIDS; Cytomegalovirus retinitis; HAART; HIV; Maintenance theraphy; Opportunistic infection

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; VIRUS ANTIGEN; VIRUS DNA; VIRUS RNA;

ADULT; ARTICLE; BLOOD CULTURE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; DISEASE MARKER; DRUG SAFETY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; INFECTION RISK; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MAINTENANCE THERAPY; MALE; MEDICAL LITERATURE; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLISHING; RELAPSE; RETINITIS; TREATMENT WITHDRAWAL; URINE CULTURE; VIRUS REACTIVATION; VIRUS REPLICATION; VISUAL SYSTEM EXAMINATION;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIGENS, VIRAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS RETINITIS; FEMALE; FOLLOW-UP STUDIES; HIV; HIV INFECTIONS; HUMANS; MALE; PROSPECTIVE STUDIES; VIRAL LOAD; VIRUS REPLICATION;

EID: 33646574946     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/9M23-QN0X-W6N8-80JD     Document Type: Article

References (49)

1. Pertel P, Hirschtich R, Phair J, et al. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immun Defic Syndr. 1992;5:1069-1074.
2. Brodt HR, Kamps BS, Gute P, et al. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS. 1997;11:1731-1738.
3. Walsh JC, Jones CD, Barnes EA, et al. Increasing survival in AIDS patients with cytomegalovirus retinitis treated with combination antiretroviral therapy including HIV protease inhibitors. AIDS. 1998;12:613-618.
4. Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet. 1997;349:1443-1445.
5. Lin DY, Warren JF, Lazzeroni LC, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy in HIV-infected patients: natural history and clinical predictors. J Retina. 2002;22(3):268-277.
6. Zambarakji H, Newson RB, Mitchell SM. CMVR diagnoses and progression of CD4 cell counts and HIV viral load measurements in HIV patients on HAART. J Ophthalmol. 2001;85:837-841.
7. Karavellas MP, Plummer DJ, Macdonald JC, et al. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J Infect Dis. 1999;179:697-700.
8. Komanduri KV, Viswanathan MN, Wieder ED, et al. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antretroviral therapy in individuals infected with HIV-1. Nat Med. 1998;4:953-956.
9. Autran B, Carcelain C, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 1997;112-116.
10. Gorochov G, Neumann AU, Kereveur A, et al. Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nature Med. 1998;4:215-221.
11. Angel JB, Kumar A, Parato K, et al. Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir. J Infect Dis. 1998;177:898-904.
12. Connor SM, Kovacs JA, Krevat S, et al. HIV infection induced changes in CD4+ T-cell phenotype and depletions within the CD4 T-cell repertoire that are not immediately restored by antiviral or immuno-based therapies. Nature Med. 1997;3:533-539.
13. Tay-Kearney ML, Enger C, Semba RD, et al. T cell subsets and cytomegalovirus retinitis in human immunodeficiency virus-infected patients. J Infect Dis. 1997;176:790-794.
14. Schrier RD, Freeman WER, Wiley CA, McCutchan JA. Immune predispositions for cytomegalovirus retinitis in AIDS. The HNRC Group. J Clin invest 1997;95:1741-1746.
15. Cooney EL. Clinical indicators of immune restoration following highly active antiretroviral therapy. Clin Infect Dis. 2002;34:224-233.
16. Whitcup SM, Fortin E, Nussenblatt RB, et al. Therapeutic effect of combination antiretroviral therapy on cytomegalovirus retinitis. JAMA. 1997;277:1519.
17. MacDonald JC, Torriani FJ, Morse LS, et al. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J Infect Dis. 1998;177:1182-1187.
18. Tural C, Romen J, Sirera G, et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J Infect Dis. 1908;177:1080-1083.
19. Jabs DA, Bolton SG, Dunn JP, et al. Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy. Am J Ophthalmology. 1998;126:817-822.
20. Vrabec TR, Baldassano VF, Whitcut SM, et al. Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts. Ophthalmology. 1998;105(7):1259-1264.
21. Whitcup SM, Fortin E, Lindblad AS, et al. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. JAMA. 1999;282(17):1633-1637.
22. Jouan M, Savès M, Tubiana R, et al. Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy. AIDS. 2001;15:23-31.
23. Curi A, Muralha A, Muralha L, Pavesio C. Suspension of anticytomegalovirus maintenance therapy following immune recovery due to hightly active antiretrovirall therapy. Br J Ophthalmol. 2001;85:471-473.
24. Berenguer J, González J, Pulido F, et al. Discontinuation of secondary prophylaxis in patients with cytomegalovirus retinitis who have responded to highly active antiretroviral therapy. Clin Infect Dis. 2002;34:394-397.
25. Sklar P, Agyemang A, Monastra R, et al. Five-year follow-up of a cohort of profoundly immunosuppressed patients discontinuing therapy for cytomegalovirus retinitis. AIDS. 2004;18(3):567-569.
26. Torriani FJ, Freeman WR, Christopher J, et al. CMV retinitis recurs after stopping treatment in virological and immunological failures of potent antiretroviral therapy. AIDS. 2000;14:173-180.
27. Schaller UC, Walli RK, Mueller AJ, Klauss V. Regression of cytomegalovirus retinitis in AIDS patients without systemic maintenance anticytomegalovirus therapy treated with highly active antiretroviral therapy. Ophthalmology. 1999;96(12):829-831.
28. Wohl DA, Kendall MA, Owens S, et al., for the ACTG 379 Study Team. The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy. HIV Clin Trials. 2005:6(3):136-146.
29. Kirk O, Reiss P, Uberti-Foppa C, et al. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med. 2002;137:239-250.
30. Engler HD, Selepak ST. Effect of centrifuging shell vials at 3500 × g on detection of viruses in clinical specimens. J Clin Microbiol. 1994;32:1580-1582.
31. Gema G, Revello MG, Percivalle E, et al. Comparison of a different immuostaining technique and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia. J Clin Microbiol. 1992;30:1232-1237.
32. Witt DJ, Kemper M, Stead A, Sillekens P, et al. Analytical perfomance and clinical utility of a nucleic acid sequence-based amplification assay for detection of cytomegalovirus infection. J Clin Microbiol. 2000;39:3994-3999.
33. Wendland T, Furrer H, Vemazza PL, et al. HAART in HIV-infected patients: restoration of antigen-specific CD4 T cell responses in vitro is correlated with CD4 memory T-cell reconstitution whereas improvement in delayed type hypersensitivity is related to a decrease in viremia. AIDS. 1999;13:1857-1862.
34. Holbrook JT, Davis MD, Hubbard LD, et al. Studies of ocular complications of AIDS Research Group. Risk factors for advancement of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. Arch Opthalmol. 2000;118:1196-1204.
35. Jabs D, Van Natta M, Thorne J, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Ophthalmology. 2004;111:2224-2231.
36. Department of Health and Human Services, Centers for Disease Control and Prevention. Treating opportunistic infections among HIV-infected adults and adolescents. Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR. 2004;53:RR-15.
37. Lalonde RG, Boivin G, Deschenes JG, et al. Canadian consensus guidelines for the management of cytomegalovirus disease in HIV/AIDS. Can J Infect Dis. 2004; 15(6):327-335.
38. Walmsley S, Mazzulli T, Krajden M. Long term predictive value of a single cytomegalovirus (CMV) DNA PCR assay for CMV disease in human immunodeficiency virus-infected patients. J Clin Microbiol. 1998;36:281-283.
39. Shinkai M, Bozzettee SA, Powderly W, et al. Utility of urine and leukocyte cultures and plasma DNA polymerase chain reaction for identification of AIDS patients at risk for developing human cytomegalovirus disease. J Infect Dis. 1997;175:302-308.
40. Dodt KK, Jacobsen PH, Hofmann B, et al. Development of cytomegalovirus (CMV) disease may be predicted in HIV-infected patients by CMV polymerase chain reaction and the antigenemia test. AIDS. 1997;11:F21-F28.
41. Bowen EF, Sabin CA, Wilson P, et al. Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease. AIDS. 1996;11:889-893.
42. Francisci D, Tosti A, Baldelli F, et al. The pp65 antigenaemia test as a predictor of cytomegalovirus-induced end-organ disease in patients with AIDS. AIDS. 1997;1341-1345.
43. Rasmussen L, Zipeto D, Wolitz RA, et al. Risk for retinitis in patients with AIDS can be assessed by quantitation of threshold levels of cytomegalovirus DNA burden in blood. J Infect Dis. 1997;176:1146-1155.
44. Walmsley S, O'Rourke K, Mortimer C, Rachlis A, Fong, I, Mazzulli T. Predictive value of cytomegalovirus antigenemia and Digene Hybrid Capture DNA Assay for CMV disease in HIV infection. Clin Infect Dis. 1998;27:573-560.
45. Bowen EF, Emery VC, Wilson P, et al. Cytomegalovirus polymerase chain reaction viraemia in patients receiving ganciclovir maintenance therapy for retinitis. AIDS. 1998;12:605-611.
46. Komanduri KV, Feinberg J, Hutchins RK, et al. Loss of cytomegalovirus-specific CD4+ T cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T cell counts and recurrent retinitis. J Infect Dis. 2001;183:1285-1289.
47. Weinberg A, Wohl DA, Barrett RJ, et al. Inconsistent reconstitution of cytomegalovirus-specific cell-mediated immunity in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. J Infect Dis. 2001;184:707-712.
48. Jacobson MA, Schrier R, McCune JM, et al. Cytomegalovirus (CMV)-specific CD4+ T lymphocyte immune function in long-term survivors of AIDS-related CMV end-organ diseases who are receiving potent antiretroviral therapy. J Infect Dis. 2001;183:1399-1404.
49. Gema G, Giampiero P, Genini E, et al.. Declining, levels of rescued lymphoproliferative response to human cytomegalovirus in AIDS patients with or without HCMV disease following long term HAART. J AIDS. 2001;28(4):320-331.